

정신분열병 환자의 도파민 D₁ 수용체 유전자형과 치료반응간의 연관백종우* · 이민수*[†] · 이충순** · 임동준* · 함원훈***The Association between the Dopamine D₁ Receptor Genotype and Treatment Response in Korean Schizophrenic PatientsJong Woo Paik, M.D.,* Min Soo Lee, M.D., Ph.D.,*[†] Choong Soon Rhee, M.D., Ph.D.,**
Dong Ju Lim, M.D.,* Won Hun Ham, Ph.D.,***

ABSTRACT

Background : Dopamine receptors have been regarded as a strong candidate involved in etiology of schizophrenia and a target for various antipsychotic drugs. The purpose of our study was to investigate whether dopamine D₁ receptor(DRD1) gene polymorphisms would predict the treatment response to antipsychotics in schizophrenia.

Method : One hundred thirty - four schizophrenic patients, who met DSM - criteria for schizophrenia were entered into a 48 - week study. The psychopathology of the patients was assessed at baseline, 12th, 24th 48th weeks of treatment by PANSS. Responders were defined by a 20% of the reduction in total PANSS score at end point. The genomic DNA fragment corresponding to nucleotides of dopamine D₁ receptor gene was amplified by polymerase chain reaction(PCR).

Result: Neither allelic frequencies nor genotypes for dopamine D₁ receptor differed significantly between responders and non - responders. Also, there was no difference of changes of PANSS scores among three genotype groups of the dopamine D₁ receptor.

Conclusion : Allelic variation in the dopamine D₁ gene is not associated with individual differences in antipsychotic response.

KEY WORDS : Dopamine D₁ receptor · Receptor gene · Schizophrenia · Treatment response.

서
문

가

, 15~65%

(Melzer Ranjan

가

, 가 가

Department of Psychiatry, College of Medicine, Korea University, Seoul, Korea 1996).

Yong-In Mental Hospital, Kyunggi-do, Korea

Sungkyunkwan University School of Pharmacy, Seoul, Korea

†교신저자: , 136 - 705 5가 126 - 1

) (02) 920 - 5354,) (02) 923 - 3507

E - mail) leeminsu@unitel.co.kr

(Arranz 1998a).

가

(Sawaguchi 1991), (positron emission tomography) DRD1 가 (Wisconsin card sorting test) 가 (Okubo 1997a), (Okubo 1997b). D₁ 가 가 가 D₁ 가 (Brown Herz 1989). 가 HVA 5 - HIAA HVA HVA (Chang 1990 ; Davidson 1991). 가 HVA (Picker 1992) DRD2 DRD4 가 (Arranz 1998a ; Peter 1994). (Arranz 1998b)가 D₁ 가 D₁ 가 202 가 D₁ 가 23 D₁ (Rao 1991). 1990 D₁ 가 (Coon 1993 ; Liu 1995 ; Dollfus 1996). (1997) (pharmacogenetics) D₁ (Wong 2000). D₁ 가 (prefrontal cortex) 가 (working memory)

연구대상 및 방법

1. 연구대상

1998 4 1999 3 20 65 4 (DSM -) 가

2. 연구방법

1) 유전자형 분석

(1) Genomic DNA 1.5ml 13,000rpm 1 pellet ACE shocking solution(NH₄Cl 8g, Na₂EDTAH₂O 1g, KH₂PO₄ 0.1g 1l) 500 μl 3 pellet 400 μl nucleic lysis Buffer[Tris(pH 8.0) 10mM,

NaCl 400mM, EDTA 2mM] pellet
 10% SDS 27 μl proteinase K 10 μl 가 56
 2 saturated NaCl 135 μl
 15 . 13000rpm 1
 2

DNA . DNA 70%
 , 100 μl .
 (2) (Polymerase Chain Reaction : PCR)

D₁ 5' untranslation region -
 48 A G Forward 5 - ACTGA-
 CCCCTATTCCCTGCT - 3' Reverse 5 - AGCACAGACCAG-
 CGTGTTC - 3' primer(Sven et al 1994)

Template DNA 200ng, primer 20 pmol,
 dNTP 200 μM, Taq polymerase 3U(Takara, Japan)
 25 μl 94 10 1
 94 30 , 60 30 , 72 30
 35 , 72 10 1

(3)
 B1 B2 PCR Ddel
 2% ethidium bro-
 mide (ultraviolet transillumi-
 nator) polaroid (polaroid, film 667)

2) 임상증상의 평가

가 48 12
 Positive and Negative Syndrome Scale(PANSS) (Kay
 1987) PANSS
 20%
 (B1B1, B1B2, B2B2)
 가 가 가
 가 workshop
 video tape 가 가 0.8

3. 통계분석

(B1B1, B1B2,
 B2B2) chi - square
 PANSS 48
 repeated measure ANOVA

SPSS/PC+ version 10.0 , 0.05

결 과

1. 인구사회학적 특성

134 (77 , 57)
 , 48 (28 , 20)
 86 (49 , 37)
 38.1 ± 6.69 , 39.85 ± 7.15 ,
 22.36 ± 7.91 , 23.75 ± 6.43 .
 , 가

(가
) 1065 ± 694mg, 1128 ± 781mg
 (1).

2. 도파민 D₁ 수용체의 유전자형에 따른 분포

B1B1 4 3.0%, B1B2 28 20.9%, B2B2
 102 76.1% B1 B2
 23.9%, 97.0% (2).

3. 도파민 D₁ 수용체의 유전자형과 치료반응과의 관계

48 12
 PANSS

Table 1. Demographic data in samples of Korean schizophrenic patients

	Responders	Non-responders
Sex		
Male	28(36.4)	49(63.6)
Female	20(35.1)	37(64.9)
Age(yrs)	38.10 ± 6.69	39.85 ± 7.15
Age of onset(yrs)	22.36 ± 7.91	23.75 ± 6.43
Type		
Paranoid	22(40.0)	33(60.0)
Disorganized	3(30.0)	7(70.0)
Catatonic	2(100)	0(0)
Undifferentiated	13(29.5)	31(70.5)
Residual	5(25.0)	25(75.0)
Family history		
Present	4(3.0)	8(6)
Unknown	21(15.7)	44(32.8)
None	23(17.2)	34(25.4)
Previous hospitalization	3.00 ± 1.61	3.98 ± 2.87
Dosage	1065 ± 694mg	1128 ± 781mg
(%)		

중심 단어 : D₁

참고문헌

- 김정일 · 이민수 · 광동일(1997) : 정신분열병 환자의 도파민 D₁ 수용체 대립 유전자 연합. *생물정신의학*. 4(2) : 218-223
- American Psychiatric Association(1994) : *Diagnostic and Manual of Mental disorders, 4ed.* American Psychiatric Association, Washington
- Arranz MJ, Tao Li, J. Munro, X. Robin Murray, David A. Collier (1998a) : Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response. *Pharmacogenetics* 8 : 481-484
- Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham P(1998b) : Evidence for association between polymorphism in the promoter and coding regions of the 5-HT_{2A} receptor gene and response to clozapine. *Mol Psychiatry* 3 : 61-66
- Brown WA, Herz LR(1989) : Response to neuroleptic drugs as a device for classifying schizophrenia. *Schizophrenia Bull* 15 : 123-129
- Chang WH, Chen TY, Lin SK, Lung FW, Lin WL, Hu WH, Yeh EK (1990) : Plasma Catecholamine metabolites in schizophrenics : Evidence for the two-subtype concept. *Bio Psychiatry* 27 : 510-518
- Coon H, Byerley W, Holik J, Hoff M, Myles-Worsley M, Lamfelt L, Sokoff P, Schwartz J-C, Waldo M, Freedman R, Plaetke R (1993) : Linkage analysis of schizophrenia with five dopamine receptor gene innine pedigree. *Am J Hum Genet* 52 : 327-334
- Davidson M, Kahn RS, Knott P(1991) : The effect of neuroleptic treatment on plasma homovanillic acid concentrations and schizophrenic symptoms. *Arch Gen Psychiatry* 48 : 910-913
- Den Boer JA, van Megen HJ, Fleischhacker WW, Louwerens JW, Slaap BR, Westenberg HG, Burrows GD, Srivastava ON (1995) : Differential effects of the D₁-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia. *Psychopharmacology(Berl)* 121(3) : 317-22
- Dollfus S, Champion D, Vasse T, Preterre P, Laurent C, d'Amato T, Thibaut F, Fetit M, Mallet J(1996) : Association study between dopamine D₁, D₂, D₃, and D₄ receptor genes and schizophrenia defined by several diagnostic systems. *Biological Psychiatry*. 40(5) : 419-21, 1996 Sep 1.
- Hess EJ, Bracha HS, Kleinman JE, Creese I(1987) : Dopamine receptor subtype imbalance in schizophrenia. *Life Sciences*. 40(15) : 1487-97
- Ginovart N, Lundin A, Farde L, Halldin C, Beckman L, Swahn CG, Pauli S, Sedvall G(1997) : PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease. *Brain*, 120 : 503-14
- Javitch JA, Kaufmann CA(1991) : Schizophrenia and the dopamine D₂ receptor. In *Review of Psychiatry, Vol 10, Ed by Tasman A, Goldfinger SM, Washington DC, American Psychiatric Press, 434-479*
- Kay SR, Fiszbein A, Opler LA(1987) : The positive and negative syndrome scale(PANSS) for schizophrenia. *Schizophr Bull* 13 : 261
- Karlsson P, Farde L, Halldin C, Swahn CG, Sedvall G, Foged C, Hansen KT, Skrum-sager B(1993) : PET examination of [11C] NNC 687 and [11C]NNC 756 as new radioligands for the D₁-dopamine receptor. *Psychopharmacology*. 113(2) : 149-56
- Knable MB, Hyde TM, Murray AM, Herman MM, Kleinman JE(1996) : A postmortem study of frontal cortical dopamine D₁ receptors in schizophrenics, psychiatric controls, and normal controls. *Biol Psychiatry*, 40 : 12, 1191-9
- Liu Q, Sobell JL, Heston LL, Sommer SS(1995) : Screening the dopamine D₁ receptor gene in 131 schizophrenics and eight alcoholics. identification of polymorphism but lack functionally significant sequence changes. *Am J Med Genet* 60 : 165-171
- Melzer HY, Ranjan R(1996) : Chap 12. Efficacy of Novel antipsychotics Drugs in Treatment-Refractory Schizophrenia. (In) *Antipsychotics*. Csernansky JG(ed), Berlin, Springer Verlag, pp333-357
- Okubo Y, Suhara T, Suzuki K(1997a) : Decreased prefrontal dopamine D₁ receptors in schizophrenia revealed by PET. *Nature* 385(6617) : 634-636
- Okubo Y, Suhara T, Sudo Y, Toru M(1997b) : Possible role of dopamine D₁ receptors in schizophrenia. *Mol Psychiatry*, 2(4) : 291-292
- Peter A. Rao, David Picker, Pabli V Gejmen, Anca Ram, Eliot S. Gershon, Joel Gelernter(1994) : Allelic variation in the D₄ Dopamine receptor(DRD₄) gene does not predict response to clozapine. *Arch gen psychiatry* 51 : 912-917
- Pickar D, Owen RR, Ritman RE, Konichi E, Gutierrez R, Rappaport MH(1992) : Clinical and biologic response to clozapine in the patients with schizophrenia. Crossover comparison with fluphenazine. *Arch Gen Psychiatry* 49 : 345-353
- Rao PA, Molinoff P, Joyce JN(1991) : Ontogeny of dopamine D₁ and D₂ receptor subtype in rat basal ganglia ; A quantattive autoraphic study. *Dev Brain Res* 60 : 161-177
- Saha N, Tsoi WF, Low PS, Basair J, Tay JSH(1994) : Lack of association of dopamine D₃ receptor gene polymorphism in Chinese schizophrenic males. *Psychiatr Genet* 4 : 201-204
- Sawaguchi T, Goldman RP(1991) : D₁-dopamine receptors in prefrontal cortex : Involve- ment in working memory. *Science* 1991 ; 251 : 947-950.
- Sedvall G, Farde L(1995) : Chemical brain anatomy in schizophrenia. *Lancet*. 346(8977) : 743-9
- Suhara T, Nakayama K, Inoue O, Fukuda H, Shimizu M, Mori A, Tateno Y(1992) : D₁ dopamine receptor binding in mood disorders measured by positron emission tomography. *Psychopharmacology*. 106(1) : 14-8
- Sven C, Markus M.N, Jeanette E, Peter P(1994) : Detection of four polymorphic sites in the human dopamine D₁ receptor gene(DRD₁) *Human molecular genetics* 3(1) : 209
- Wong AH, Buckle CE, Van Tol HH(2000) : Polymorphisms in dopamine receptors : what do they tell us?. *European Journal of Pharmacology* 410 : 183-203